Premium
Serial Dilutions on Synthetic Peptide‐Based Assays Can Resolve Dual Seroreactivity to HIV‐1 and HIV‐2
Author(s) -
Soriano V.,
Gutiérrez M.,
Heredia A.,
Bravo R.,
Aguilera O.,
Mas A.,
Hewlett I.,
Baquero M.,
GonzálezLahoz J.
Publication year - 1996
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1046/j.1423-0410.1996.7110067.x
Subject(s) - human immunodeficiency virus (hiv) , virology , serial dilution , immunology , medicine , biology , pathology , alternative medicine
Several authors have reported a high rate of dual seroreactivity to HIV‐1 and HIV‐2 in areas where both viruses are prevalent [1, 2]. For instance, Ghys et al. [2] pointed out that 38% of HIV‐seropositive female sex workers in Abidjan, Côte d'Ivoire, show dual seroreactivity to HIV‐1 and HIV‐2. Moreover, the authors make the point that in this area endemic for both viruses, dual seroreactivity using synthetic peptide‐based assays, such as Pepti‐LAV 1+2 (Diagnostics Pasteur, Paris, France), more likely reflects truly dual infections than cross‐reactivity in subjects with either HIV‐1 or HIV‐2 monotypic infections. Since a recent report from Senegal has claimed that HIV‐2 might protect against subsequent infection by HIV‐1 [3], a very high rate of true coinfections is likely to be in conflict with this hypothesis.